In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli

The present work concerns the heterologous expression of the intracellular domain harbouring the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Protein expression was improved thanks to the deletion of a 13-amino acid peptide of the juxtamembrane region (JM). The recombinant proteins were produced as a glutathione S-transferase (GST) fusion in Escherichia coli, and the solubilisation was performed by sarkosyl addition during extraction. The produced proteins spontaneously dimerize allowing the activation of the tyrosine kinase domain in the presence of [γ-32P]ATP. The activity assay has revealed the autophosphorylation of EGFR proteins which was decreased in the presence of genistein. Our system could facilitate the screening of EGFR inhibitors without the need of adding an exogenous substrate.

[1]  Karim Jellali,et al.  Monoclonal antibodies as cancer therapeutics. , 2012, Recent patents on biotechnology.

[2]  Linda J Pike,et al.  Mechanics of EGF Receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging , 2011, Proceedings of the National Academy of Sciences.

[3]  Karim Jellali,et al.  The offer of chemistry to targeted therapy in cancer. , 2011, Recent patents on biotechnology.

[4]  Zhuchu Chen,et al.  Purification and characterization of recombinant extracellular domain of human HER2 from Escherichia coli. , 2007, Protein expression and purification.

[5]  Bing Sun,et al.  Expression of intracellular domain of epidermal growth factor receptor and generation of its monoclonal antibody. , 2004, Cellular & molecular immunology.

[6]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[7]  B. Liedberg,et al.  Interactions between the juxtamembrane domain of the EGFR and calmodulin measured by surface plasmon resonance. , 2002, Cellular signalling.

[8]  K. Lackey,et al.  Comparison of the Biochemical and Kinetic Properties of the Type 1 Receptor Tyrosine Kinase Intracellular Domains , 2002, The Journal of Biological Chemistry.

[9]  K. Makino,et al.  Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.

[10]  S. Cohen,et al.  Glycosylation-induced Conformational Modification Positively Regulates Receptor-Receptor Association , 2001, The Journal of Biological Chemistry.

[11]  K. Inouye,et al.  Formation of the Ras Dimer Is Essential for Raf-1 Activation* , 2000, The Journal of Biological Chemistry.

[12]  R. Edwards,et al.  Dimerisation of maize glutathione transferases in recombinant bacteria , 1999, Plant Molecular Biology.

[13]  A. Ożyhar,et al.  GST-Induced dimerization of DNA-binding domains alters characteristics of their interaction with DNA. , 1998, Protein expression and purification.

[14]  J. Martín-Nieto,et al.  The human epidermal growth factor receptor contains a juxtamembrane calmodulin-binding site. , 1998, Biochemistry.

[15]  A. Ullrich,et al.  Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase. , 1993, Biochemistry.

[16]  A. Ullrich,et al.  Generation of recombinant cytoplasmic domain of epidermal growth factor receptor with intrinsic protein tyrosine kinase activity. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[17]  R. Cerione,et al.  Expression of epidermal growth factor receptor sequences as E. coli fusion proteins: applications in the study of tyrosine kinase function. , 1990, Biochemical and biophysical research communications.

[18]  P. Seeburg,et al.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.

[19]  O. Hermanson,et al.  A basic peptide within the juxtamembrane region is required for EGF receptor dimerization. , 2005, Experimental cell research.

[20]  O. Hamid.  Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. , 2004, Journal of the American Pharmacists Association : JAPhA.

[21]  A. Mishra,et al.  Protein Expression and Purification , 2002 .